Clinical Trial

A Clinical Study of LM103 Injection in the Treatment of Advanced Solid Tumors

Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated August 2, 2022 (before its estimated May 30, 2024 completion). Its status may not reflect the trial's current state.
Summary
This is a single-arm, open-label, exploratory study to evaluate safety and efficacy of LM103 Injection in patients with advanced solid tumors. The purpose of this study is to evaluate the safety and tolerability, antitumor activity and immunoreactivity.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2022-05-05.
Status change: Not Yet Recruiting → Recruiting 2022-08-01
Trial Details
NCT Number NCT05366478
Lead Sponsor Suzhou BlueHorse Therapeutics Co., Ltd.
Conditions Melanoma, Non Small Cell Lung Cancer, Cervical Carcinoma
Enrollment 15 participants
Start Date 2022-05-30
Primary Completion 2024-05-30 (estimated)
Study Completion 2029-05-30 (estimated)
Updated on ClinicalTrials.gov 2022-08-02